Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 5, 2006, Pages 371-374

  Karlström, Olle ^a   Ståhle, Lars ^a   Perrin, Luc ^b   Tegude, Heike ^c   Sönnerborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; RADIATION DETECTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; VIRUS LOAD;

ANTI-HIV AGENTS; CEREBROSPINAL FLUID; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33744822785     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540500469535     Document Type: Article

References (18)

1. Enting, RH and Hoetelmans, RM and Lange, JM and Burger, DM and Beijnen, JH and Portegies, P. (1998) Antiretroviral drugs and the central nervous system AIDS, 12, pp. 1941-55.
2. Tashima, KT and Caliendo, AM and Ahmad, A and Gormley, JM and Fiske, WD and Brennan, JM et al. (1999) Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy J Infect Dis, 180, pp. 862-4.
3. Martin, C and Sönnerborg, A and Svensson, J.O and Ståhle, L. (1999) Indinavir-based treatment of HIV-1 infected patients: Efficacy in the central nervous system AIDS, 13, pp. 1227-32.
4. Yilmaz, A and Ståhle, S and Hagberg, L and Svennerholm, B and Fuchs, D and Gisslén, M. (2004) Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ ritonavir regimen Scand J Infect Dis, 36, pp. 823-8.
5. Aweeka, F and Jayewardene, A and Staprans, S and Bellibas, SE and Kearney, B and Lizak, P et al. (1999) Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex J Acquir Immune Defic Syndrome, 20, pp. 39-43.
6. Haas, DW and Clough, LA and Johnson, BW and Harris, VL and Spearman, P and Wilkinson, GR et al. (2000) Evidence of a source of HIV Type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma AIDS Res Hum Retroviruses, 16, pp. 1491-1502.
7. Solas, C and Laffeuillade, A and Halfon, P and Chdapaud, S and Hittinger, G and Lacarelle, B. (2003) Discrepances between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients Antimicrobial Agents Chemother, 47, pp. 238-43.
8. Fellay, J and Marzolini, C and Meaden, ER and Back, DJ and Buclin, T and Chave, JP et al. (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug transporter 1: A pharmacogenetics study Lancet, 359, pp. 30-6.
9. Yerly, S and Rutscchmann, OT and Marrchal, F and Hirschel, B and Perrin, L. (2000) Time of initiation of antiviral therapy: Impact of HIV-1 viraemia. The Swiss Cohort Study AIDS, 14, pp. 243-9.
10. Schwab, M and Schaeffler, E and Marx, C and Fromm, MF and Kaskas, B and Metzler, J et al. (2003) Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis Gastroenterology, 124, pp. 26-33.
11. Viracept manufacturer report, Agouron Pharmaceuticals Inc, revised September 2004.
12. Eggers, C and Hertogs, K and Sturenburg, HJ and van Lunzen, J and Stellbrink, HJ. (2003) Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration AIDS, 17, pp. 1897-1906.
13. Sacktor, N and Tarwater, PM and Skolasky, RL and McArthur, JC and Selnes, OA and Becker, J et al. (2001) CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing Neurology, 57, pp. 542-4.
14. De Luca, A and Ciancio, BC and Larussa, D and Murri, R and Cingolani, A and Rizzo, MG et al. (2002) Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals Neurology, 59, pp. 342-7.
15. Antinori, A and Giancola, ML and Grisetti, S and Soldani, F and Alba, L and Liuzzi, G et al. (2002) Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients AIDS, 16, pp. 1867-76.
16. Lee, CG and Gottesman, MM and Cardarelli, CO and Ramachandra, M and Jeang, KT and Ambudkar, SV et al. (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter Biochemistry, 37, pp. 3594-601.
17. HoffmeyerS, BurkO, Von RichterO, Arnold HP, BrockmöllerJ, JohneAFunctional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of 1 allele with P-glycoprotein expression and activity in vivo. PNAS 2000; 97:3473-8.
18. Kim, RB and Leake, BF and Choo, EF and Dresser, GK and Kubba, SV and Schwarz, UI et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans Clinical Pharmacology and Therapeutics, 70, pp. 189-99.